53 related articles for article (PubMed ID: 34609077)
1. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Hochhaus A; Wang J; Kim DW; Kim DDH; Mayer J; Goh YT; le Coutre P; Takahashi N; Kim I; Etienne G; Andorsky D; Issa GC; Larson RA; Bombaci F; Kapoor S; McCulloch T; Malek K; Yau L; Ifrah S; Hoch M; Cortes JE; Hughes TP;
N Engl J Med; 2024 May; ():. PubMed ID: 38820078
[TBL] [Abstract][Full Text] [Related]
2. Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study.
Minami Y; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Dawson MK; Matsumura I
Int J Hematol; 2024 Jun; ():. PubMed ID: 38888812
[TBL] [Abstract][Full Text] [Related]
3. In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.
Han HJ; Kim JJ; Pyne D; Travas A; Ambalavanan A; Kimura S; Deininger MW; Kim JW; Kim DDH
Leukemia; 2024 Feb; 38(2):412-415. PubMed ID: 38155246
[No Abstract] [Full Text] [Related]
4. Safety and Efficacy of Asciminib in Chronic Myeloid Leukemia Patient with Chronic Kidney Diseases: A Case Report.
Alshurafa A; Afshan Adil ; Yassin MA
Case Rep Oncol; 2024; 17(1):96-100. PubMed ID: 38229976
[TBL] [Abstract][Full Text] [Related]
5. Refractory pancytopenia upon initiation of asciminib in tyrosine kinase inhibitor-resistant chronic myeloid leukemia.
Tessier S; Aiad M; Longo S; Wilson M; Faroun Y
Int J Crit Illn Inj Sci; 2023; 13(2):78-81. PubMed ID: 37547190
[TBL] [Abstract][Full Text] [Related]
6. The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib.
Leske IB; Hantschel O
Leukemia; 2024 Jun; ():. PubMed ID: 38879610
[No Abstract] [Full Text] [Related]
7. Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing
Gleixner KV; Filik Y; Berger D; Schewzik C; Stefanzl G; Sadovnik I; Degenfeld-Schonburg L; Eisenwort G; Schneeweiss-Gleixner M; Byrgazov K; Sperr WR; Mayer J; Lion T; Valent P
Am J Cancer Res; 2021; 11(9):4470-4484. PubMed ID: 34659899
[TBL] [Abstract][Full Text] [Related]
8. Future Directions in Chronic Phase CML Treatment.
Javidi-Sharifi N; Hobbs G
Curr Hematol Malig Rep; 2021 Dec; 16(6):500-508. PubMed ID: 34648120
[TBL] [Abstract][Full Text] [Related]
9. Control of Ph
Ansari S; Verma M
Med Oncol; 2023 Jul; 40(8):237. PubMed ID: 37439908
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
Li YF; Combes FP; Hoch M; Lorenzo S; Sy SKB; Ho YY
Clin Pharmacokinet; 2022 Oct; 61(10):1393-1403. PubMed ID: 35764773
[TBL] [Abstract][Full Text] [Related]
11. Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review.
Kumar V; Singh P; Gupta SK; Ali V; Verma M
Mol Cell Biochem; 2022 Apr; 477(4):1261-1279. PubMed ID: 35129779
[TBL] [Abstract][Full Text] [Related]
12. Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia.
Verhagen NE; Koenderink JB; Blijlevens NMA; Janssen JJWM; Russel FGM
Pharmaceutics; 2023 Oct; 15(11):. PubMed ID: 38004514
[TBL] [Abstract][Full Text] [Related]
13. Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
Padala S; Cortes J
Haematologica; 2023 Nov; 108(11):2913-2918. PubMed ID: 37102603
[TBL] [Abstract][Full Text] [Related]
14. Intestinal Metabolism of Diclofenac by Polymorphic UGT2B17 Correlates with its Highly Variable Pharmacokinetics and Safety across Populations.
Ahire D; Heyward S; Prasad B
Clin Pharmacol Ther; 2023 Jul; 114(1):161-172. PubMed ID: 37042794
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents.
Hoch M; Huth F; Sato M; Sengupta T; Quinlan M; Dodd S; Kapoor S; Hourcade-Potelleret F
Clin Transl Sci; 2022 Jul; 15(7):1698-1712. PubMed ID: 35616006
[TBL] [Abstract][Full Text] [Related]
16. Asciminib: First Approval.
Deeks ED
Drugs; 2022 Feb; 82(2):219-226. PubMed ID: 35041175
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Asciminib When Taken With Imatinib or With Food.
Hoch M; Zack J; Quinlan M; Huth F; Forte S; Dodd S; Aimone P; Hourcade-Potelleret F
Clin Pharmacol Drug Dev; 2022 Feb; 11(2):207-219. PubMed ID: 34609077
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]